Abstract
The aim of this study was to investigate possible influences of a set of markers in the FAT gene (rs2306987, rs2306990, rs2637777 and rs2304865) on efficacy and tolerability of aripiprazole in the treatment of schizophrenic patients. Efficacy was assessed at baseline and weeks 1, 2, 4, 6, 8 and 12 using the Clinical Global Impression Severity and Improvement scale (CGI-S; CGI-I), the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms scale. Side effects were evaluated by means of the Simpson–Angus Scale for Extrapyramidal Symptoms, the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale. Multivariate analyses were employed to test possible influences of single nucleotide polymorphisms on clinical and safety variables. Analysis of haplotypes was also performed. No relevant association between FAT variants and clinical or safety scores was observed. Haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well. Our data suggest no association between investigated alleles and genotypes in FAT and response to aripiprazole. However, because several limitations characterize the present study, further investigations on larger studies are required.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Goodwin, M. & Yap, A. S. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 35, 839–844 (2004).
Tepass, U., Truong, K., Godt, D., Ikura, M. & Peifer, M. Cadherins in embryonic and neural morphogenesis. Nat. Rev. Mol. Cell. Biol. 1, 91–100 (2000).
Yagi, T. & Takeichi, M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 14, 1169–1180 (2000).
Pedrosa, E., Stefanescu, R., Margolis, B., Petruolo, O., Lo, Y., Nolan, K. et al. Analysis of protocadherin alpha gene enhancer polymorphism in bipolar disorder and schizophrenia. Schizophr. Res. 102, 210–219 (2008).
Mahoney, P. A., Weber, U., Onofrechuk, P., Biessmann, H., Bryant, P. J. & Goodman, C. S. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 67, 853–868 (1991).
Jeanes, A., Gottardi, C. J. & Yap, A. S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920–6929 (2008).
Abou Jamra, R., Becker, T., Georgi, A., Feulner, T., Schumacher, J., Stromaier, J. et al. Genetic variation of the FAT gene at 4q35 is associated with bipolar affective disorder. Mol. Psychiatry 13, 277–284 (2008).
Blair, I. P., Chetcuti, A. F., Badenhop, R. F., Scimone, A., Moses, M. J., Adams, L. J. et al. Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Mol. Psychiatry 11, 372–383 (2006).
Friddle, C., Koskela, R., Ranade, K., Hebert, J., Cargill, M., Clark, C. D. et al. Full-genome scan for linkage in 50 families segregating the bipolar affective disease phenotype. Am. J. Hum. Genet. 66, 205–215 (2000).
McInnis, M. G., Lan, T. H., Willour, V. L., McMahon, F. J., Simpson, S. G., Addington, A. M. et al. Genome-wide scan of bipolar disorder in 65 pedigrees: supportive evidence for linkage at 8q24, 18q22, 4q32, 2p12, and 13q12. Mol. Psychiatry 8, 288–298 (2003).
Willour, V. L., Zandi, P. P., Huo, Y., Diggs, T. L., Chellis, J. L., MacKinnon, D. F. et al. Genome scan of the fifty-six bipolar pedigrees from the NIMH genetics initiative replication sample: chromosomes 4, 7, 9, 18, 19, 20, and 21. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121, 21–27 (2003).
Porteous, D. Genetic causality in schizophrenia and bipolar disorder: out with the old and in with the new. Curr. Opin. Genet. Dev. 18, 229–234 (2008).
Ivleva, E., Thaker, G. & Tamminga, C. A. Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr. Bull. 34, 734–742 (2008).
Craddock, N., O'Donovan, M. C. & Owen, M. J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32, 9–16 (2006).
Pae, C. U., Serretti, A., Chiesa, A., Mandelli, L., Lee, C., Kim, J. et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur. Neuropsychopharmacol. 19, 562–570 (2009).
Guy, W. Clinical Global Impression. Assessment Manual for Psychopharmacology 217–222 (Department of Health Education and Welfare, Washington, DC, USA, 1976).
Flemenbaum, A. & Zimmermann, R. L. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol. Rep. 32, 783–792 (1973).
Andreasen, N. C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 7, 49–58 (1989).
Simpson, G. M. & Angus, J. W. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. Suppl. 212, 11–19 (1970).
Barnes, T. R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672–676 (1989).
Branch, P. R. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom. 4, 3–6 (1975).
StatSoft I: STATISTICA per Windows, StatSoft Italia srl, Vigonza (PD) (1995).
Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005).
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum, Hillsdale, New Jersey, 1988).
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N. et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 13, 2699–2708 (2004).
Hwu, H. G., Lin, M. W., Lee, P. C., Lee, S. F., Ou-Yang, W. C. & Liu, C. M. Evaluation of linkage of markers on chromosome 6p with schizophrenia in Taiwanese families. Am. J. Med. Genet. 96, 74–78 (2000).
Acknowledgements
This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0). The founding source had no other role in the preparation of the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pae, CU., Chiesa, A., Mandelli, L. et al. No influence of FAT polymorphisms in response to aripiprazole. J Hum Genet 55, 32–36 (2010). https://doi.org/10.1038/jhg.2009.117
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2009.117
